C5 and Alzheimer disease: We showed that C5a-AFFITOPE® vaccination is able to target the pro-inflammatory complement activation product C5a, thus preventing enhanced microglia activation in the hippocampus, reducing memory decline and Aβ pathology in a model of AD.